The product

Magnecell's first product will be for cartilage repair to treat both traumatic cartilage injuries and arthritis.

Magnecell has demonstrated the growth of cartilage from human mesenchymal stem cells and the target­ing of such stem cells to the site of injury using its patented technology. This will lead to new treatments with significant benefits over current approaches:

The market

Each year, over 15 million people worldwide suffer from failure of the knee-joint alone. In the USA, it is estimated that insurance providers pay $41 billion annually to treat joint deterioration. Key amongst the diseases causing cartilage deterioration is osteoarthritis. Osteoarthritis affects nearly 21 million people in the USA, accounting for 25% of GP visits. It is estimated that 80% of the population will have radiographic evidence of osteoarthritis by age 65. Treatments for cartilage problems are limited especially for osteoarthritis.